# Biotech Daily Digest â€” 2026-02-25

**31 items from 3 sources**

## Summary by Source

- Endpoints News: 7 items
- Fierce Biotech: 8 items
- arXiv q-bio: 16 items


## Endpoints News

- **[Polymer nanoparticle startup BreezeBio raises $60M for mRNA diabetes therapy](https://endpoints.news/polymer-nanoparticle-startup-raises-60m-for-mrna-diabetes-therapy/)**  
  _Wed, 25 Feb 2026 12:00:38 +0000_  
  BreezeBio, a startup founded a decade ago to develop new delivery technologies for genetic medicines, has raised $60 million to start clinical trials of its first program, it announced Wednesday.
 The therapy is meant to ...

- **[Industry groups lay legal groundwork against pricing demos](https://endpoints.news/industry-groups-lay-legal-groundwork-against-pricing-demos/)**  
  _Tue, 24 Feb 2026 20:36:25 +0000_  
  Pharma trade groups are laying the foundation for potential legal challenges to two CMS pricing demonstrations that they say are much broader than legally allowed and aren't actually intended to save patients money.

 The rebukes ...

- **[UCLA spinout raises $11M to test microbiome-based weight loss therapy](https://endpoints.news/ucla-spinout-raises-11m-to-test-microbiome-based-weight-loss-therapy/)**  
  _Tue, 24 Feb 2026 19:38:18 +0000_  
  Bloom Science believes it has stumbled on a new approach to weight loss: a pill containing two strains of bacteria that alter the gut microbiome to replicate the effects of the ketogenic diet.
 The company ...

- **[BioMarin fails to find buyer, pulls Roctavian gene therapy off market](https://endpoints.news/biomarin-fails-to-find-buyer-pulls-roctavian-gene-therapy-off-market/)**  
  _Tue, 24 Feb 2026 16:17:44 +0000_  
  BioMarin's previous CEO wanted to offer money-back guarantees to insurers for covering its hemophilia gene therapy Roctavian. Investors in the company may wish that such a promise on performance could have ...

- **[Patient dies in MacroGenics' cancer study, FDA puts trial on hold](https://endpoints.news/patient-dies-in-macrogenics-cancer-study-fda-puts-trial-on-hold/)**  
  _Tue, 24 Feb 2026 15:40:28 +0000_  
  The FDA has placed a partial clinical hold on MacroGenicsâ€™ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday.

 The patient who died ...

- **[Beam Therapeutics' new PKU program; Protara's bladder cancer data](https://endpoints.news/beam-therapeutics-new-pku-program-protaras-bladder-cancer-data/)**  
  _Tue, 24 Feb 2026 15:35:10 +0000_  
  Plus, news about Bristol Myers Squibb, Catalent, Angelini Pharma, Quiver Bioscience and Brainomix:

 ðŸ¥¼ Beam Therapeutics' gene editing plans: The company said it will develop multiple gene editing therapies tailored to ...

- **[Abcuro drug fails muscle weakness trial, development to continue](https://endpoints.news/abcuro-drug-fails-muscle-weakness-trial-development-to-continue/)**  
  _Tue, 24 Feb 2026 15:24:47 +0000_  
  Abcuroâ€™s monoclonal antibody failed the main endpoint and key secondary goals in a Phase 2b/3 trial for a rare and chronic autoimmune disease with no FDA-approved treatments.

 The Newton, MA-based biotech


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/after-gene-therapy-exit-pfizer-locks-global-license-beam-gene-editing-candidate" hreflang="en">After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate</a>](https://www.fiercebiotech.com/biotech/after-gene-therapy-exit-pfizer-locks-global-license-beam-gene-editing-candidate)**  
  _Feb 25, 2026 9:01am_  
  After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeuticsâ€™ liver-targeted gene editing candidate.

- **[<a href="https://www.fiercebiotech.com/biotech/gsk-pays-950m-cash-canadian-biotech-and-its-winrevair-blood-pressure-drug" hreflang="en">GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug</a>](https://www.fiercebiotech.com/biotech/gsk-pays-950m-cash-canadian-biotech-and-its-winrevair-blood-pressure-drug)**  
  _Feb 25, 2026 4:42am_  
  Like Merck & Co.â€™s PAH drug Winrevairâ€”which brought in $1.4 billion last yearâ€”35Pharma's HS235 targets the activin receptor signaling pathway.

- **[<a href="https://www.fiercebiotech.com/biotech/werewolf-weighs-sale-or-merger-cash-reserves-whimper" hreflang="en">Werewolf weighs sale or merger as cash reserves whimper</a>](https://www.fiercebiotech.com/biotech/werewolf-weighs-sale-or-merger-cash-reserves-whimper)**  
  _Feb 24, 2026 5:14pm_  
  With its cash cache set to run out by the fourth quarter of this year, Werewolf Therapeutics is prowling the biotech landscape for a deal to keep its pipeline afloat. The immuno-oncology outfit is weighing a full range of strategic options, including selling or merging the company, with the goal of giving shareholdersâ€¦

- **[<a href="https://www.fiercebiotech.com/biotech/analyst-china-no-longer-bargain-basement-biotech-acquisitions" hreflang="en">After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst</a>](https://www.fiercebiotech.com/biotech/analyst-china-no-longer-bargain-basement-biotech-acquisitions)**  
  _Feb 23, 2026 2:14pm_  
  The average upfront value for a licensing deal between a Western biopharma company and its Chinese counterpart increased from $52 million to $172 million between 2022 and early 2026, according to data shared with Fierce Biotech from biopharma intelligence firm Evaluate.

- **[<a href="https://www.fiercebiotech.com/biotech/harbour-helps-form-new-biotech-licensing-anti-ctla-4-asset-11b-biobucks-deal" hreflang="en">Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal</a>](https://www.fiercebiotech.com/biotech/harbour-helps-form-new-biotech-licensing-anti-ctla-4-asset-11b-biobucks-deal)**  
  _Feb 24, 2026 2:25pm_  
  Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion.

- **[<a href="https://www.fiercebiotech.com/biotech/fda-freezes-enrollment-macrogenics-cancer-trial-after-patient-death" hreflang="en">FDA freezes enrollment in MacroGenics cancer trial after patient death</a>](https://www.fiercebiotech.com/biotech/fda-freezes-enrollment-macrogenics-cancer-trial-after-patient-death)**  
  _Feb 24, 2026 1:55pm_  
  The FDA has ordered MacroGenics to halt enrollment in a phase 2 trial of the biotechâ€™s lead candidate lorigerlimab following severe side effects that led to one patient death.

- **[<a href="https://www.fiercebiotech.com/biotech/evinova-multiplies-ai-clinic-development-partnerships-astellas-and-astrazeneca-deals" hreflang="en">Evinova reels in AI clinical development deals with Astellas and AstraZeneca</a>](https://www.fiercebiotech.com/biotech/evinova-multiplies-ai-clinic-development-partnerships-astellas-and-astrazeneca-deals)**  
  _Feb 24, 2026 10:44am_  
  Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by partnering with Evinova and using its AI platform designed to speed up clinical development.

- **[<a href="https://www.fiercebiotech.com/biotech/astellas-vir-engage-17b-deal-masked-prostate-cancer-bispecific" hreflang="en">'The perfect partner': Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific</a>](https://www.fiercebiotech.com/biotech/astellas-vir-engage-17b-deal-masked-prostate-cancer-bispecific)**  
  _Feb 23, 2026 1:15pm_  
  Astellas is aiding Vir Biotechnologyâ€™s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager for prostate cancer.


## arXiv q-bio

- **[Cross-Chirality Generalization by Axial Vectors for Hetero-Chiral Protein-Peptide Interaction Design](https://arxiv.org/abs/2602.20176)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.20176v1 Announce Type: new 
Abstract: D-peptide binders targeting L-proteins have promising therapeutic potential. Despite rapid advances in machine learning-based target-conditioned peptide design, generating D-peptide binders remains largely unexplored. In this work, we show that by injecting axial featurâ€¦

- **[KEMP-PIP: A Feature-Fusion Based Approach for Pro-inflammatory Peptide Prediction](https://arxiv.org/abs/2602.20198)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.20198v1 Announce Type: new 
Abstract: Pro-inflammatory peptides (PIPs) play critical roles in immune signaling and inflammation but are difficult to identify experimentally due to costly and time-consuming assays. To address this challenge, we present KEMP-PIP, a hybrid machine learning framework that integâ€¦

- **[Regressor-guided Diffusion Model for De Novo Peptide Sequencing with Explicit Mass Control](https://arxiv.org/abs/2602.20209)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.20209v1 Announce Type: new 
Abstract: The discovery of novel proteins relies on sensitive protein identification, for which de novo peptide sequencing (DNPS) from mass spectra is a crucial approach. While deep learning has advanced DNPS, existing models inadequately enforce the fundamental mass consistencyâ€¦

- **[Unveiling Scaling Laws of Parameter Identifiability and Uncertainty Quantification in Data-Driven Biological Modeling](https://arxiv.org/abs/2602.20495)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.20495v1 Announce Type: new 
Abstract: Integrating high-dimensional biological data into data-driven mechanistic modeling requires rigorous practical identifiability to ensure interpretability and generalizability. However, coordinate identifiability analysis often suffers from numerical instabilities near sâ€¦

- **[Tipping points in complex ecological systems](https://arxiv.org/abs/2602.20702)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.20702v1 Announce Type: new 
Abstract: Tipping points are one of the hot topics in modern physics of complex systems. But what is a tipping point? A generic definition declares it as ``a state of the system where a small change in its parameters can lead to a significant change in its properties''. Additionaâ€¦

- **[Adaptation by Cumulative Selection](https://arxiv.org/abs/2602.20883)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.20883v1 Announce Type: new 
Abstract: Biological systems like long-lived clonal organisms, holobionts and clades challenge traditional evolutionary thinking since they adapt without populations or reproduction. This paper aims to provide an overarching theoretical framework which encompasses standard Darwinâ€¦

- **[Age Structured Epidemic Model under Vaccination with Vector Transmission](https://arxiv.org/abs/2602.21150)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.21150v1 Announce Type: new 
Abstract: Dengue remains a major global public health concern due to its high mortality and economic burden. Mathematical modeling is essential to understand its transmission mechanisms and for evaluating intervention strategies. In this paper, we formulate a vector host model inâ€¦

- **[Topological shape transform for thymus structures](https://arxiv.org/abs/2602.18889)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.18889v1 Announce Type: cross 
Abstract: The Euler characteristic transform (ECT) is an emerging and powerful framework within topological data analysis for quantifying the geometry of shape. The applicability of ECT has been limited due to its sensitivity to noisy data. Here, we introduce SampEuler, a novelâ€¦

- **[Targeted T2-FLAIR Dropout Training Improves Robustness of nnU-Net Glioblastoma Segmentation to Missing T2-FLAIR](https://arxiv.org/abs/2602.20218)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.20218v1 Announce Type: cross 
Abstract: Purpose: To determine whether targeted T2 fluid-attenuated inversion recovery (T2-FLAIR) dropout training improves glioblastoma MRI tumor segmentation robustness to missing T2-FLAIR without degrading performance when T2-FLAIR is available. Materials and Methods: Thisâ€¦

- **[Protein Language Models Diverge from Natural Language: Comparative Analysis and Improved Inference](https://arxiv.org/abs/2602.20449)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2602.20449v1 Announce Type: cross 
Abstract: Modern Protein Language Models (PLMs) apply transformer-based model architectures from natural language processing to biological sequences, predicting a variety of protein functions and properties. However, protein language has key differences from natural language, sâ€¦

- **[Intercellular contact is sufficient to drive Fibroblast to Myofibroblast transitions](https://arxiv.org/abs/2503.01834)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2503.01834v3 Announce Type: replace 
Abstract: Fibroblast cells play a key role in maintaining the extracellular matrix. During wound healing, fibroblasts differentiate into highly contractile myofibroblasts, which secrete extracellular matrix proteins like collagen to facilitate tissue repair. Under normal condâ€¦

- **[Modelling the transmission and impact of Omicron variants of Covid-19 in different ethnicity groups in Aotearoa New Zealand](https://arxiv.org/abs/2508.15077)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2508.15077v2 Announce Type: replace 
Abstract: Previous pandemics, including influenza pandemics and Covid-19, have disproportionately impacted M\=aori and Pacific populations in Aotearoa New Zealand. The reasons for this are multi-faceted, including differences in socioeconomic deprivation, housing conditions aâ€¦

- **[Morphology-Aware Peptide Discovery via Masked Conditional Generative Modeling](https://arxiv.org/abs/2509.02060)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2509.02060v3 Announce Type: replace 
Abstract: Peptide self-assembly prediction offers a powerful bottom-up strategy for designing biocompatible, low-toxicity materials for large-scale synthesis in a broad range of biomedical and energy applications. However, screening the vast sequence space for categorizationâ€¦

- **[Harmonic fields and the mechanical response of a cellular monolayer to ablation](https://arxiv.org/abs/2510.05193)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2510.05193v2 Announce Type: replace 
Abstract: Multicellular tissues, such as the epithelium coating a developing embryo, often combine complex tissue shapes with heterogeneity in the spatial arrangement of individual cells. Discrete approximations, such as the cell vertex model, can accommodate these geometricâ€¦

- **[Monte Carlo Tree Diffusion with Multiple Experts for Protein Design](https://arxiv.org/abs/2509.15796)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2509.15796v2 Announce Type: replace-cross 
Abstract: The goal of protein design is to generate amino acid sequences that fold into functional structures with desired properties. Prior methods combining autoregressive language models with Monte Carlo Tree Search (MCTS) struggle with long-range dependencies and suâ€¦

- **[Predicting Metabolic Dysfunction-Associated Steatotic Liver Disease using Machine Learning Methods: A Retrospective Cohort Study](https://arxiv.org/abs/2510.22293)**  
  _Wed, 25 Feb 2026 00:00:00 -0500_  
  arXiv:2510.22293v3 Announce Type: replace-cross 
Abstract: Background and Aims: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) affects 30-40% of U.S. adults and is the most common chronic liver disease. Although often asymptomatic, progression can lead to cirrhosis. We developed a prediction model toâ€¦
